Budapest, Hungary

Ágnes Née Behr Papp

This inventor holds 1 USPTO granted patent. Top assignee: Gyogyszerkutato Intezet Kft.. Active years: 2001.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ágnes Née Behr Papp. Retrieved from https://idiyas.com/inventor/andaacutegnes-nandeacutee-behr-papp

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

Average Co-Inventor Count = 23.0

ph-index = 1


Company Filing History:


Years Active: 2001

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ágnes Née Behr Papp: Innovator in Pharmaceutical Chemistry

Introduction

Ágnes Née Behr Papp is a notable inventor based in Budapest, Hungary. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative work on pyridazinone derivatives.

Latest Patents

He holds a patent for "3(2H)-pyridazinone derivatives and pharmaceutical compositions containing these compounds." This invention relates to R-2-[3-([1,4]benzodioxan-2-ylmethylamino)-1-propyl]-3(2H)-pyridazionone, which is represented by a specific chemical formula. His work in this area has the potential to impact the development of new pharmaceutical compositions.

Career Highlights

Ágnes Née Behr Papp has been associated with Gyogyszerkutato Intezet Kft., where he has furthered his research and development efforts. His dedication to innovation in the pharmaceutical sector is evident through his patent and ongoing research.

Collaborations

He has collaborated with notable colleagues, including Péter Mátyus and László Hársing, who have contributed to his research endeavors. Their combined expertise enhances the potential impact of their work in the pharmaceutical field.

Conclusion

Ágnes Née Behr Papp is a distinguished inventor whose work in pharmaceutical chemistry exemplifies innovation and collaboration. His contributions, particularly in the area of pyridazinone derivatives, highlight the importance of research in developing new therapeutic options.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…